maximum weight loss tirzepatide surmount trials SURMOUNT‐1 study design. This is a phase 3, multicenter, randomized, ECO 2026: SURMOUNT-MAINTAIN proves tirzepatide

[2] - [5] Recent phase 2 clinical trial data evaluating the activity and safety of GLP-3 in subjects with type 2 diabetes demonstrate its pronounced effects on both glycemic control and body weight reduction

Most were similar to adverse effects observed in existing GLP-1 therapies

Diabetic Retinopathy Progression and Macular Edema Development Zepbound and Vision Loss: The relationship between Zepbound and vision loss also includes the progression of diabetic retinopathy and the development of macular edema , particularly in patients with pre-existing diabetic eye disease

Sermorelin, although slower, aligns with a gradual, steady approach to weight loss